The effect of jararhagin, a metalloproteinase from Bothrops jararaca venom, on pro-inflammatory cytokines released by murine peritoneal adherent cells.
The release of pro-inflammatory cytokines (IL-1beta, IL-6 and TNF-alpha) from murine peritoneal adherent cells (MPAC) was studied after exposure to jararhagin, a metalloproteinase/disintegrin isolated from Bothrops jararaca venom. MPACs were treated with LPS (lipopolysaccharide), jararhagin, or EDTA-inactivated jararhagin for up to 24h. Following incubation, the culture supernatant was assayed by ELISA for the presence of cytokines, while the cells were analysed for viability and cytokine mRNA expression. The cells exposed to native jararhagin released TNF-alpha and IL-1beta after 4 and 24h respectively. When MPACs were exposed to Jararhagin treated with EDTA, TNF-alpha and IL-1beta production was sustained throughout the culture period and IL-6 production was observed. TNF-alpha, IL-6 and IL-1beta mRNA were detected 4h after stimulation with either native or EDTA-treated jararhagin. Addition of jararhagin to LPS stimulated cells resulted in a dramatic decrease in the release of IL-6 and TNF-alpha. RT-PCR showed that this inhibition does not occur at the transcriptional level and further experiments showed that jararhagin degraded soluble cytokines by proteolytic activity. This study suggests that jararhagin induces TNF-alpha, IL-1beta and IL-6 expression, which may be rapidly degraded by its proteolytic activity.
Clissa
P B
PB
Laboratório de Imunopatologia, Instituto Butantan, Av. Vital Brasil, 1500, Butantan. CEP: 05503-900, São Paulo, Brazil. clissapb@usp.br
Laing
G D
GD
Theakston
R D
RD
Mota
I
I
Taylor
M J
MJ
Moura-da-Silva
A M
AM
D000818:Animals; D017837:Bothrops; D002470:Cell Survival / Q000187:drug effects; D003435:Crotalid Venoms / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000201:enzymology / Q000494:pharmacology* / Q000633:toxicity; D016207:Cytokines / Q000494:pharmacology*; D004338:Drug Combinations; D004492:Edetic Acid / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D007249:Inflammation; D007375:Interleukin-1 / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism*; D007502:Iron Chelating Agents; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000276:immunology*; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010529:Peritoneal Cavity / Q000166:cytology*; D010975:Platelet Aggregation Inhibitors; D012333:RNA, Messenger / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D000097146:Bothrops jararaca Venom
D003435:Crotalid Venoms; D016207:Cytokines; D004338:Drug Combinations; D004492:Edetic Acid; D007375:Interleukin-1; D015850:Interleukin-6; D007502:Iron Chelating Agents; D008070:Lipopolysaccharides; D008666:Metalloendopeptidases; D010975:Platelet Aggregation Inhibitors; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D000097146:Bothrops jararaca Venom